Nanology Labs has designed and is developing Manganescan®, a novel theranostic agent (MRI contrast agent/Radio-sensitizer) that allows detection of brain tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents(GBCAs), can cross the blood brain barrier and enables early and precise detection and targeting of brain cancer.

Biotechnology

Pharmaceutical

QurCan Therapeutics Inc.

QurCan Therapeutics Inc.'s headquarters in Toronto, Canada

Description

People (2)

Azhar Zahoor Abbasi

John Reid

Jobs